Dermavant Sciences has linked its plaque psoriasis prospect tapinarof to deepening improvements in outcomes over the first year of treatment. The number of responders rose in an interim analysis of a 40-week extension study, which followed successful phase 3 clinical trials that read out last year.
Copyright © 2021,